Bli medlem
Bli medlem

Du är här

2015-04-20

Biofrontera AG: Biofrontera establishes subsidiary in the US

Biofrontera AG / Biofrontera establishes subsidiary in the US. Processed and
transmitted by NASDAQ OMX Corporate Solutions. The issuer is solely
responsible for the content of this announcement.
* Preparing for scheduled market entry in 2016
* Monica Tamborini appointed CEO of Biofrontera's US operations

Leverkusen, 20 April 2015 - Biofrontera AG (AIM/FSE: B8F), the
biopharmaceutical company focusing on skin cancer, has formed a wholly-owned
US subsidiary, Biofrontera Inc., registered in Wilmington, Delaware. This
company is intended to lay the ground for marketing and sales activities upon
the expected FDA approval for the products Ameluz® and BF-RhodoLED® in 2016.

Monica Tamborini has been appointed CEO of Biofrontera's US operations. Monica
has over 20 years' experience managing US companies in the healthcare sector.
After earning master's degrees in economics and business administration with
summa cum laude from Boston University und Suffolk University, and receiving
the "Delta Alpha PI Society Award", Monica worked in various sectors before
joining the pharmaceutical industry. Since then, Monica has held various
positions as CFO and COO. In addition to her expertise in finance Monica has,
as Managing Director of Calix Consulting, in recent years concentrated on the
communication with the Food and Drug Administration (FDA) and the development
of quality management systems, which are mandatory for pharmaceutical and
medical device businesses.

Commenting, CEO of Biofrontera, Prof. Dr. Hermann Lübbert, said: "We are very
happy that we will be able to rely on Monica's broad expertise when
establishing the infrastructure for the distribution of our products in the
US.

"An efficient infrastructure, supported by a perfectly well-attuned quality
management system, is the foundation of every pharmaceutical company's
success. Monica Tamborini's professional background makes her the perfect
choice for the development and management of our US business. Since we are
expecting FDA approval for our products by the summer of 2016, it is
extremely important to start preparing now for the distribution of our
products. Monica will initially conduct further market analyses on which the
decision will be based whether the cooperation with another distribution
partner will be required."

Ends

Enquiries, please contact:

------------------------------------------------------------------------
| Biofrontera AG +49 (0) 214 87 63 2 0 |
| |
|Prof. Hermann Lübbert, Chief Executive Officer press@biofrontera.com |
|Thomas Schaffer, Chief Financial Officer |
| www.biofrontera.com |
| IR Germany: Brainwell Asset Solutions +49 (0) 152 08931514 |
| |
|Jürgen Benker |
| Nomad and Broker: Shore Capital +44(0) 20 7408 4090 |
| |
|Bidhi Bhoma / Toby Gibbs |
| IR UK: Seton Services +44(0) 20 7603 6797 |
| |
|Toni Vallen |
| Financial PR: Gable Communications +44(0) 20 7193 7463 |
| |
|John Bick +44 (0)7872 061007 |
------------------------------------------------------------------------
Background:

TheBiofrontera Group
(FSE/AIM: B8F, ISIN DE0006046113) is a biopharmaceutical company specialising
in the development, sale and distribution of drugs and medical cosmetics for
the care and treatment of skin diseases. Biofrontera's most important product
isAmeluz®
, a prescription drug which is approved in Europe for the treatment of mild
and moderate actinic keratosis (superficial skin cancer) with photodynamic
therapy (light therapy). Biofrontera is the first German pharmaceutical
start-up company to obtain centralised approval for a drug it has developed
itself. The company also plans for Ameluz®to be approved for basal cell
carcinoma and is currently preparing for approval in other countries,
especially in the largest pharmaceutical market in the world, the United
States.

The company also markets the Belixos®dermatological range of cosmetics.
Belixos®products contain combinations of active substances extracted from
plants, relieve itching and redness and are used for the regenerative care of
chronic skin conditions such as atopic dermatitis or psoriasis. At the
moment, Belixos®cream, gel and scalp tonic are available through Amazon.

The Biofrontera Group was established in 1997 by Prof. Dr Hermann Lübbert, the
Chairman of the company's Management Board, and has its headquarters in
Leverkusen, Germany.

www.biofrontera.com

This communication expressly or implicitly contains certain forward-looking
statements concerning the business activities of Biofrontera AG. These
forward-looking statements reflect the opinion of Biofrontera at the time of
this communication and involve certain known and unknown risks. The actual
results achieved by Biofrontera may differ significantly from future results
or performances which are published in its forward-looking statements.
Biofrontera assumes no responsibility to update its forward-looking
statements.

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biofrontera AG via Globenewswire

HUG#1912330

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.